CSP Specialty Pharmacy Exam: Questions with Correct Answers
(2026/2027 Edition)
SECTION 1: Intake and Patient Onboarding
Question 1. Which of the following best defines a "specialty medication" in
contemporary pharmacy practice?
A. Any medication that requires prior authorization
B. A high-cost medication used to treat complex, chronic, or rare conditions that may
require special handling, administration, or patient monitoring
C. Any medication that is not available at a retail pharmacy
D. A medication that is only available through mail order
Correct Answer: B. A high-cost medication used to treat complex, chronic, or rare
conditions that may require special handling, administration, or patient monitoring
Rationale: Specialty medications are defined by high cost, complex disease states,
special handling requirements, and intensive clinical monitoring. While many require
prior authorization, not all do, making Option A incorrect. Option C is incorrect because
retail pharmacies may dispense certain specialty medications. Option D is incorrect
because specialty medications are not restricted to mail order.
Question 2. During the benefit investigation process for a new specialty pharmacy
patient, which component is essential to accurately determine the patient's
out-of-pocket cost?
A. The patient's Social Security number
B. The medication's tier placement and the patient's benefit design (deductible, copay,
coinsurance)
C. The prescriber's NPI number only
D. The pharmacy's DEA registration status
Correct Answer: B. The medication's tier placement and the patient's benefit design
(deductible, copay, coinsurance)
,Rationale: A comprehensive benefit investigation requires verification of the drug's
formulary tier, deductible status, copay/coinsurance rates, and out-of-pocket maximum
to calculate patient responsibility. Option A is incorrect because a Social Security
number is not required for benefit verification. Option C is incorrect because the
prescriber's NPI alone does not determine patient cost. Option D is incorrect because
DEA registration is unrelated to insurance benefit investigation.
Question 3. A patient with rheumatoid arthritis is prescribed adalimumab. The
pharmacy receives a prior authorization (PA) denial from the commercial payer stating
"step therapy required." What is the most appropriate next step?
A. Dispense the medication and bill the patient cash
B. Contact the prescriber to discuss the denial and initiate an appeal with supporting
clinical documentation
C. Transfer the prescription to a competing specialty pharmacy
D. Inform the patient that the medication is not covered and no alternatives exist
Correct Answer: B. Contact the prescriber to discuss the denial and initiate an appeal
with supporting clinical documentation
Rationale: Step therapy denials require prescriber involvement to provide clinical
documentation supporting medical necessity or documenting failure of required
first-line agents. Option A is incorrect because cash dispensing without exploring
coverage options is not financially feasible for most patients and bypasses appropriate
clinical pathways. Option C is incorrect because transferring the prescription does not
resolve the PA requirement. Option D is incorrect because it misrepresents the
availability of appeal options.
Question 4. Which patient profile is most likely to qualify for manufacturer-sponsored
patient assistance programs (PAPs) for specialty medications?
A. A patient with commercial insurance and a $50 copay
B. A patient with Medicare Part D, no supplemental coverage, and an annual income at
250% of the federal poverty level
C. An uninsured patient with an annual income at 300% of the federal poverty level
D. A patient with Medicaid coverage and a $0 copay
, Correct Answer: C. An uninsured patient with an annual income at 300% of the federal
poverty level
Rationale: Manufacturer PAPs typically serve uninsured or underinsured patients, with
income eligibility thresholds commonly set between 200% and 500% of the federal
poverty level. Option A is incorrect because commercially insured patients with
manageable copays generally do not qualify for PAPs. Option B is incorrect because
Medicare beneficiaries are often excluded from manufacturer PAPs due to federal
anti-kickback statute considerations; they may qualify for independent foundation
assistance instead. Option D is incorrect because Medicaid patients with full coverage
do not require PAP assistance.
Question 5. A 45-year-old patient with multiple sclerosis presents to the specialty
pharmacy for initiation of fingolimod. During intake, the pharmacist discovers the
patient has a history of bradycardia and is currently taking propranolol. The insurance
requires a PA. Which sequence represents the most appropriate clinical and operational
workflow?
A. Dispense immediately, then obtain PA retroactively, and schedule cardiology referral
after first dose
B. Hold dispensing, notify prescriber of bradycardia risk and drug interaction, obtain
baseline ECG, and submit PA with cardiac monitoring documentation
C. Submit PA without clinical information, dispense upon approval, and counsel on
dizziness only
D. Transfer to retail pharmacy because fingolimod is not a specialty medication
Correct Answer: B. Hold dispensing, notify prescriber of bradycardia risk and drug
interaction, obtain baseline ECG, and submit PA with cardiac monitoring documentation
Rationale: Fingolimod carries a boxed warning for bradycardia and requires baseline
ECG and monitoring due to first-dose heart rate effects. The concurrent use of
propranolol increases bradycardia risk. Option A is incorrect because retroactive PA is
not compliant and initiating therapy without cardiac evaluation is unsafe. Option C is
incorrect because submitting a PA without relevant clinical information is likely to result
in denial and fails to address the serious drug-disease interaction. Option D is incorrect
(2026/2027 Edition)
SECTION 1: Intake and Patient Onboarding
Question 1. Which of the following best defines a "specialty medication" in
contemporary pharmacy practice?
A. Any medication that requires prior authorization
B. A high-cost medication used to treat complex, chronic, or rare conditions that may
require special handling, administration, or patient monitoring
C. Any medication that is not available at a retail pharmacy
D. A medication that is only available through mail order
Correct Answer: B. A high-cost medication used to treat complex, chronic, or rare
conditions that may require special handling, administration, or patient monitoring
Rationale: Specialty medications are defined by high cost, complex disease states,
special handling requirements, and intensive clinical monitoring. While many require
prior authorization, not all do, making Option A incorrect. Option C is incorrect because
retail pharmacies may dispense certain specialty medications. Option D is incorrect
because specialty medications are not restricted to mail order.
Question 2. During the benefit investigation process for a new specialty pharmacy
patient, which component is essential to accurately determine the patient's
out-of-pocket cost?
A. The patient's Social Security number
B. The medication's tier placement and the patient's benefit design (deductible, copay,
coinsurance)
C. The prescriber's NPI number only
D. The pharmacy's DEA registration status
Correct Answer: B. The medication's tier placement and the patient's benefit design
(deductible, copay, coinsurance)
,Rationale: A comprehensive benefit investigation requires verification of the drug's
formulary tier, deductible status, copay/coinsurance rates, and out-of-pocket maximum
to calculate patient responsibility. Option A is incorrect because a Social Security
number is not required for benefit verification. Option C is incorrect because the
prescriber's NPI alone does not determine patient cost. Option D is incorrect because
DEA registration is unrelated to insurance benefit investigation.
Question 3. A patient with rheumatoid arthritis is prescribed adalimumab. The
pharmacy receives a prior authorization (PA) denial from the commercial payer stating
"step therapy required." What is the most appropriate next step?
A. Dispense the medication and bill the patient cash
B. Contact the prescriber to discuss the denial and initiate an appeal with supporting
clinical documentation
C. Transfer the prescription to a competing specialty pharmacy
D. Inform the patient that the medication is not covered and no alternatives exist
Correct Answer: B. Contact the prescriber to discuss the denial and initiate an appeal
with supporting clinical documentation
Rationale: Step therapy denials require prescriber involvement to provide clinical
documentation supporting medical necessity or documenting failure of required
first-line agents. Option A is incorrect because cash dispensing without exploring
coverage options is not financially feasible for most patients and bypasses appropriate
clinical pathways. Option C is incorrect because transferring the prescription does not
resolve the PA requirement. Option D is incorrect because it misrepresents the
availability of appeal options.
Question 4. Which patient profile is most likely to qualify for manufacturer-sponsored
patient assistance programs (PAPs) for specialty medications?
A. A patient with commercial insurance and a $50 copay
B. A patient with Medicare Part D, no supplemental coverage, and an annual income at
250% of the federal poverty level
C. An uninsured patient with an annual income at 300% of the federal poverty level
D. A patient with Medicaid coverage and a $0 copay
, Correct Answer: C. An uninsured patient with an annual income at 300% of the federal
poverty level
Rationale: Manufacturer PAPs typically serve uninsured or underinsured patients, with
income eligibility thresholds commonly set between 200% and 500% of the federal
poverty level. Option A is incorrect because commercially insured patients with
manageable copays generally do not qualify for PAPs. Option B is incorrect because
Medicare beneficiaries are often excluded from manufacturer PAPs due to federal
anti-kickback statute considerations; they may qualify for independent foundation
assistance instead. Option D is incorrect because Medicaid patients with full coverage
do not require PAP assistance.
Question 5. A 45-year-old patient with multiple sclerosis presents to the specialty
pharmacy for initiation of fingolimod. During intake, the pharmacist discovers the
patient has a history of bradycardia and is currently taking propranolol. The insurance
requires a PA. Which sequence represents the most appropriate clinical and operational
workflow?
A. Dispense immediately, then obtain PA retroactively, and schedule cardiology referral
after first dose
B. Hold dispensing, notify prescriber of bradycardia risk and drug interaction, obtain
baseline ECG, and submit PA with cardiac monitoring documentation
C. Submit PA without clinical information, dispense upon approval, and counsel on
dizziness only
D. Transfer to retail pharmacy because fingolimod is not a specialty medication
Correct Answer: B. Hold dispensing, notify prescriber of bradycardia risk and drug
interaction, obtain baseline ECG, and submit PA with cardiac monitoring documentation
Rationale: Fingolimod carries a boxed warning for bradycardia and requires baseline
ECG and monitoring due to first-dose heart rate effects. The concurrent use of
propranolol increases bradycardia risk. Option A is incorrect because retroactive PA is
not compliant and initiating therapy without cardiac evaluation is unsafe. Option C is
incorrect because submitting a PA without relevant clinical information is likely to result
in denial and fails to address the serious drug-disease interaction. Option D is incorrect
